US: Pharmaceuticals
More
-
PARSIPPANY, N.J.-- Actavis Inc. said Friday a federal appeals court granted an injection that blocks it from selling a generic version of AstraZeneca PLC's asthma treatment Pulmicort Respules.
-
BUFFALO, N.Y.-- Drug-maker ISTA Pharmaceuticals has pleaded guilty in a federal case involving its eye drug Xibrom. The Justice Department says the case was settled in U.S. District Court in Buffalo Friday. ISTA, which was acquired by Rochester- based Bausch& Lomb last year, admits to promoting Xibrom for uses beyond what the Food and Drug Administration approved.
-
BUFFALO, N.Y.-- Drug-maker ISTA Pharmaceuticals has pleaded guilty in a federal case involving its eye drug Xibrom. The Justice Department says the case was settled in U.S. District Court in Buffalo Friday. ISTA, which was acquired by Rochester- based Bausch& Lomb last year, admits to promoting Xibrom for uses beyond what the Food and Drug Administration approved.
-
NEW YORK, May 24- Canada's Valeant Pharmaceuticals International is nearing a deal to acquire eye care company Bausch& Lomb Holdings Inc from Warburg Pincus LLC for about $9 billion, a person familiar with the matter said on Friday.
-
*Novo shares up 0.7 percent, outperforming sector. COPENHAGEN, May 24- Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.
-
NEW YORK-- Shares of Forest Laboratories Inc. rose to a year high Thursday after the drugmaker said Howard Solomon, its CEO for 36 years, will retire at the end of 2013..
-
NEW YORK-- Alkermes PLC said Thursday that it was profitable in its fiscal fourth quarter as it received bigger royalty payments and more revenue for drug manufacturing. Alkermes said it earned $3 million, or 2 cents per share, over the three months ended March 31.
-
*FDA panel says suvorexant safe, effective at lower doses. On Monday, the FDA's internal reviewers published a report expressing concern about suvorexant's potential to cause next-day sleepiness and impaired driving.
-
NEW YORK-- Shares of Regeneron Pharmaceuticals Inc. edged higher on Wednesday on positive clinical trial data for an experimental asthma drug. THE SPARK: The New England Journal of Medicine's website on Tuesday published the results of a study of the asthma treatment dupilumab, which Regeneron is developing with French drugmaker Sanofi.
-
TRENTON, N.J.-- Drugmaker Pfizer Inc. plans to try to sell its controlling stake in its former animal health business, Zoetis Inc., through a voluntary stock exchange with Pfizer shareholders.
-
LONDON, May 22- The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism.
-
May 22- Pfizer Inc said on Wednesday it will spin off its majority stake in animal health business Zoetis Inc to shareholders by allowing them to swap Pfizer stock for Zoetis stock at a 7 percent discount. Pfizer, the largest U.S. drugmaker, sold Zoetis shares in an initial public offering in February that raised $2.2 billion.
-
Bristol-Myers Squibb could be a big winner with a portfolio of cancer treatments under development that use a patient's own immune system to attack the disease, according to a Citi, which raised its rating on the drugmaker.
-
May 22- Pfizer Inc said on Wednesday that it would unwind its remaining stake in animal health business Zoetis Inc through an exchange offer in which shareholders can swap Pfizer stock for that of Zoetis at a discount. Giant pharmaceutical maker Pfizer spun off Zoetis shares in an initial public offering in February that raised $2.2 billion.
-
Merck inked a $5 billion share repurchase agreement with Goldman Sachs, as the drug giant looks to prop up shareholder value in face of competition from generics makers.
-
May 21- A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.
-
WESTON, Mass.-- Specialty drugmaker Biogen Idec said Tuesday it submitted a new injectable multiple sclerosis drug to the Food and Drug Administration for U.S. market approval. The company also plans to submit the drug to the European Medicines Agency in coming weeks. Shares of Biogen Idec Inc. rose $6.15, or 2.7 percent, to close Tuesday at $231.33.
-
REDWOOD CITY, Calif.-- Shares of AcelRx Pharmaceuticals Inc. hit an all-time high price Tuesday, after the specialty drugmaker said its NanoTab pain treatment system met its main goal in late-stage research, and the company is preparing to submit it to regulators for approval.
-
The revenue hit faced by Cubist Pharmaceuticals from generic competition may not be as dramatic as it has been for other drugs, Cantor Fitzgerald said Tuesday, as it raised its rating on the drugmaker.
-
May 21- A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.